OXiGENE Promotes Senior Executive


OXiGENE Promotes Senior Executive                                               
WALTHAM, Mass., July 15, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)   
(Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel  
therapeutics to treat cancer and eye diseases, today announced the promotion of 
John A. Kollins to the position of Chief Operating Officer.                     
Mr. Kollins, who most recently served as OXiGENE's Senior Vice-President and    
Chief Business Officer, will continue to lead the company's business and        
corporate development initiatives, and in addition will assume responsibility   
for the company's operations.                                                   
"Since joining OXiGENE in March 2007, John has made numerous contributions to   
the company, and has significantly advanced our corporate and business          
development initiatives," commented Richard Chin, M.D., OXiGENE's President and 
CEO. "I am very pleased to congratulate John on his promotion, and am confident 
in his ability to contribute further to OXiGENE in his new role."               
About OXiGENE                                                                   
OXiGENE is a clinical-stage biopharmaceutical company developing novel          
therapeutics to treat cancer and eye diseases. The company's major focus is     
developing VDAs that selectively disrupt abnormal blood vessels associated with 
solid tumor progression and visual impairment. OXiGENE is dedicated to          
leveraging its intellectual property and therapeutic development expertise to   
bring life-extending and -enhancing medicines to patients.                      
The OXiGENE, Inc. logo is available at                                          
http://www.primenewswire.com/newsroom/prs/?pkgid=4969                           

CONTACT:  OXiGENE, Inc.                                                         
          Investor and Media Contact:                                           
          Michelle Edwards, Investor Relations                                  
          415-315-9413                                                          
          medwards@oxigene.com